IS7202A - Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum - Google Patents

Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum

Info

Publication number
IS7202A
IS7202A IS7202A IS7202A IS7202A IS 7202 A IS7202 A IS 7202A IS 7202 A IS7202 A IS 7202A IS 7202 A IS7202 A IS 7202A IS 7202 A IS7202 A IS 7202A
Authority
IS
Iceland
Prior art keywords
compositions
treatment
inflammatory disorders
immune inflammatory
immune
Prior art date
Application number
IS7202A
Other languages
English (en)
Inventor
Keith Curtis
Borisy Alexis
Zimmermann Grant
Roydon Jost-Price Edward
Manivasakam Palaniyandi
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23277540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of IS7202A publication Critical patent/IS7202A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7202A 2001-10-05 2004-03-31 Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum IS7202A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32767401P 2001-10-05 2001-10-05
PCT/US2002/031866 WO2003030823A2 (en) 2001-10-05 2002-10-04 Combinations for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
IS7202A true IS7202A (is) 2004-03-31

Family

ID=23277540

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7202A IS7202A (is) 2001-10-05 2004-03-31 Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum

Country Status (26)

Country Link
US (3) US7253155B2 (is)
EP (2) EP1448205B1 (is)
JP (1) JP2005508346A (is)
KR (2) KR100917082B1 (is)
CN (1) CN100400044C (is)
AR (1) AR036741A1 (is)
AT (1) ATE502642T1 (is)
AU (1) AU2002334870B2 (is)
BR (1) BR0213100A (is)
CA (1) CA2461946C (is)
DE (1) DE60239558D1 (is)
DK (1) DK1448205T3 (is)
ES (1) ES2363334T3 (is)
HR (1) HRP20040388A2 (is)
IL (1) IL161267A0 (is)
IS (1) IS7202A (is)
MX (1) MXPA04003266A (is)
NO (1) NO20041386L (is)
NZ (1) NZ532310A (is)
PL (1) PL370764A1 (is)
PT (1) PT1448205E (is)
RU (1) RU2322984C2 (is)
SI (1) SI1448205T1 (is)
TW (1) TWI247605B (is)
WO (1) WO2003030823A2 (is)
ZA (1) ZA200402955B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
ES2343411T3 (es) 2003-03-26 2010-07-30 Synergy Biosystems Ltd. Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas.
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2005235369B2 (en) * 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
KR20250002752A (ko) 2007-07-23 2025-01-07 더 차이니즈 유니버시티 오브 홍콩 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
WO2009144720A1 (en) * 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
US20130338127A1 (en) * 2010-05-06 2013-12-19 Nuvo Research Inc. Triamcinolone acetonide formulations for treating dermatitis and psoriasis
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
JP6925272B2 (ja) * 2015-01-28 2021-08-25 リアルイン ライフ サイエンス リミテッド ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用
US20180289708A1 (en) * 2015-10-15 2018-10-11 Moshe Rogosnitzky Low dose oral dipyridamole compositions and uses thereof
CN111346228B (zh) * 2018-12-21 2022-01-14 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
CN114432451B (zh) * 2018-12-21 2024-02-09 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
EP3972603B1 (en) 2019-05-23 2024-09-04 Novartis AG Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CN113456618A (zh) * 2020-03-31 2021-10-01 天津金耀集团有限公司 一种复方双嘧达莫的吸入制剂及其制备方法
EP4427752A1 (en) * 2023-03-09 2024-09-11 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Dipyridamole as a novel therapy for muscular myogenesis disorders and inflammatory arthritis

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579476A (en) * 1897-03-23 Sash-holder
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
DD119586A5 (is) 1973-12-21 1976-05-05
US3934036A (en) * 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
BG36086A1 (en) * 1982-01-19 1984-09-14 Glbov Method for inducing interferon
US4387217A (en) * 1982-04-07 1983-06-07 Basf Wyandotte Corporation High foaming iodophors
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4554271A (en) * 1984-02-24 1985-11-19 The Upjohn Company Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
EP0303713B2 (en) 1987-02-23 1997-07-30 Shiseido Company Limited Percutaneous absorption promoter and dermatologic preparation for external use
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
WO1989010122A1 (en) 1988-04-27 1989-11-02 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
US5242921A (en) * 1988-04-27 1993-09-07 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
EG20321A (en) * 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
TW249754B (is) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6172066B1 (en) * 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
EP0979096B1 (en) * 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
WO1998055142A1 (en) 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
EP1036561A1 (en) 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Buccal, non-polar spray
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1246335A (zh) 1998-08-28 2000-03-08 冀聪韬 一种用于治疗皮肤病药物的制作方法
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001002497A1 (en) 1999-06-30 2001-01-11 Beltran, German Cuevas Process and product for rendering a substance flame resistant
US7358056B1 (en) * 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
CA2386457A1 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
AU1657001A (en) 1999-11-15 2001-05-30 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001047572A2 (en) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US6363471B1 (en) * 2000-01-03 2002-03-26 Advanced Micro Devices, Inc. Mechanism for handling 16-bit addressing in a processor
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
WO2002022127A1 (en) 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
MXPA04003266A (es) 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
DE10312234A1 (de) * 2002-03-20 2003-12-18 Lg Electronics Inc Betriebssteuervorrichtung und -verfahren für einen Linearkompressor
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
AU2003300469A1 (en) 2002-12-31 2004-07-29 Larry L. Augsburger Methods for making pharmaceutical dosage forms containing active cushioning components
JP2006516593A (ja) 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1999626A4 (en) 2006-01-26 2009-11-25 Combinatorx Inc METHODS, COMPOSITIONS AND NEEDS FOR TREATING MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH
EP2387994A1 (en) 2006-01-27 2011-11-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2644889A1 (en) 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions and methods for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
KR20070100400A (ko) 2007-10-10
CN1599613A (zh) 2005-03-23
WO2003030823A3 (en) 2003-07-03
PT1448205E (pt) 2011-07-05
RU2004113551A (ru) 2005-02-27
EP1448205A2 (en) 2004-08-25
CN100400044C (zh) 2008-07-09
US7253155B2 (en) 2007-08-07
MXPA04003266A (es) 2004-07-08
TWI247605B (en) 2006-01-21
DE60239558D1 (de) 2011-05-05
NO20041386L (no) 2004-05-11
EP2279742A3 (en) 2011-04-20
KR100917082B1 (ko) 2009-09-15
ATE502642T1 (de) 2011-04-15
US20110223621A1 (en) 2011-09-15
PL370764A1 (en) 2005-05-30
DK1448205T3 (da) 2011-12-12
JP2005508346A (ja) 2005-03-31
CA2461946A1 (en) 2003-04-17
AU2002334870B8 (en) 2003-04-22
KR100824491B1 (ko) 2008-04-22
AR036741A1 (es) 2004-09-29
US7915265B2 (en) 2011-03-29
BR0213100A (pt) 2004-11-30
HK1076387A1 (zh) 2006-01-20
KR20050033520A (ko) 2005-04-12
EP1448205B1 (en) 2011-03-23
RU2322984C2 (ru) 2008-04-27
EP2279742A2 (en) 2011-02-02
IL161267A0 (en) 2004-09-27
US20060234991A1 (en) 2006-10-19
CA2461946C (en) 2010-01-12
US20030119786A1 (en) 2003-06-26
AU2002334870B2 (en) 2007-10-04
HRP20040388A2 (en) 2004-10-31
NZ532310A (en) 2007-02-23
ZA200402955B (en) 2005-04-19
WO2003030823A2 (en) 2003-04-17
EP1448205A4 (en) 2007-01-03
ES2363334T3 (es) 2011-08-01
SI1448205T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1352896T3 (da) Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
IS2701B (is) Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð
NO20031443L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20020133L (no) Preparat for behandling av utvortes sekresjonsforstyrrelser
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
PT1150991E (pt) Composicoes para o tratamento da resposta inflamatoria
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
DK1458703T3 (da) Isochromanforbindelser til behandling af CNS-lidelser
IS8496A (is) Samsetningar til meðhöndlunar á fjölgunarsjúkdómum